The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Detection of NRG1 Gene Fusions in Solid Tumors
Open accessAbstract
Purpose: NRG1 gene fusions are rare but potentially actionable oncogenic drivers that are present in some solid tumors. Details regarding the incidence of these gene rearrangements are lacking. Here, we assessed the incidence of NRG1 fusions across multiple tumor types and described fusion partners. Experimental Design: Tumor specimens submitted for molecular profiling at a Clinical Laboratory Improvement Amendments (CLIA)–certified genomics laboratory and that underwent fusion testing by anchored multiplex PCR for targeted RNA sequencing were retrospectively identified. The overall and tumor-specific incidence was noted, as was the specific fusion partner. Results: Out of 21,858 tumor specimens profiled from September 2015 to December 2018, 41 cases (0.2%) harbored an NRG1 fusion. Multiple fusion partners were identified. Fusion events were seen across tumor types. The greatest incidence was in non–small cell lung cancer (NSCLC, 25), though this represented only 0.3% of NSCLC cases tested. Other tumor types harboring an NRG1 fusion included gallbladder cancer, renal cell carcinoma, bladder cancer, ovarian cancer, pancreatic cancer, breast cancer, neuroendocrine tumor, sarcoma, and colorectal cancer. Conclusions: NRG1 fusions can be detected at a low incidence across multiple tumor types with significant heterogeneity in fusion partner. See related commentary by Dimou and Camidge, p. 4865
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citation
Cited by
Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
Chevallier, M., Borgeaud, M., Addeo, A., & Friedlaender, A. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i4.217 · Cited by 316
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer
Zhang, Z., Karthaus, W. R., Lee, Y. S., Gao, V. R., Wu, C., Russo, J. W., Liu, M., Mota, J. M., Abida, W., Linton, E., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.005 · Cited by 259
Rathore, M., Zhang, W., Wright, M., Bhattacharya, R., Fan, F., Vaziri-Gohar, A., Winter, J., Wang, Z., Markowitz, S. D., Willis, J., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0633 · Cited by 14
Analysis of CD74 Occurrence in Oncogenic Fusion Proteins
(2023) · doi:10.3390/ijms242115981 · Cited by 14
Metadata
- Authors
- Jonna, S., Feldman, R. A., Swensen, J., Gatalica, Z., Korn, W. M., Borghaei, H., Ma, P. C., Nieva, J. J., Spira, A. I., Vanderwalde, A. M., Wozniak, A. J., Kim, E. S., & Liu, S. V.
- Venue
- Clinical Cancer Research
- Published
- 2019-08-15
- Volume
- 25
- Issue
- 16
- Pages
- 4966-4972
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2940163088
- Cited by
- 227
- References
- 3
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Detection of NRG1 Gene Fusions in Solid Tumors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-0160
- The paper
- Jonna, S., Feldman, R. A., Swensen, J., Gatalica, Z., Korn, W. M., Borghaei, H., Ma, P. C., Nieva, J. J., Spira, A. I., Vanderwalde, A. M., Wozniak, A. J., Kim, E. S., & Liu, S. V. (2019). Detection of NRG1 Gene Fusions in Solid Tumors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-0160
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.